Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00495872 · ClinicalTrials.gov registry record · Phase 1
Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 204
- Enrollment target
NCT00495872: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00495872 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 204 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (240% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00495872, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 204 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find the highest tolerable dose of valproic acid in combination with either dasatinib, erlotinib hydrochloride, lapatinib, lenalidomide, sorafenib, or SU011248 (sunitinib malate) that can be given to patients with advanced cancer. The safety of each combination of the study drugs will be studied as well.
Interventions
- DRUG Lenalidomide
- DRUG Dasatinib
- DRUG Sorafenib
- DRUG Erlotinib
- DRUG Lapatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 204 participants |
| Start Date | 2007-06 |
| Phase | Phase 1 |
What the finished NCT00495872 record still lists
NCT00495872 is an interventional study that assigns participants to a tested intervention. The registered 204 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (240% higher).
The record links to 0 conditions, and to 5 interventions - of which Lenalidomide is the first listed.
NCT00495872 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00495872 about?
NCT00495872 is a clinical study titled "Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor". The goal of this clinical research study is to find the highest tolerable dose of valproic acid in combination with either dasatinib, erlotinib hydrochloride, lapatinib, lenalidomide, sorafenib, or SU011248 (sunitinib malate) that can be given to patients with advanced cancer. The safety of each com...
What is the current status of trial NCT00495872?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 204 participants. The study started on 2007-06.
What interventions are being tested in trial NCT00495872?
The interventions under investigation include: Lenalidomide (DRUG), Dasatinib (DRUG), Sorafenib (DRUG), Erlotinib (DRUG), Lapatinib (DRUG).
Who is sponsoring clinical trial NCT00495872?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00495872's enrollment target sits among peer trials
204 256th of 2000 higher than 1,743 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03481010 · 204 participants · NA
Periacetabular Osteotomy With and Without Arthroscopic Management of Central Compartment Pathology
- NCT04249830 · 204 participants · NA
Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Young Adults
- NCT04503395 · 204 participants · NA
ShOrt neCK AAA RAndomized Trial - ESAR and FEVAR: SOCRATES
- NCT04793776 · 204 participants · NA
Manage Emotions to Reduce Aggression (MERA)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia